A GSK-led consortium looks to break ground with a new class of antibiotic, pushing into a pivotal

Jason Mast

Editor

After watching a slew of biotechs crash and burn after fielding a lineup of freshly approved antibiotics, GlaxoSmithKline is hoping to achieve something new in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A GSK-led consortium looks to break ground with a new class of antibiotic, pushing into a pivotal

Jason Mast

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Less than two years after blockbuster IPO, Acelyrin merges with Alumis to combine cash, assets

Longtime Sandoz exec announces retirement; Lilly appoints head of India

Bristol Myers prunes pipeline amid new round of cost cuts

Novo Nordisk takes aim at Roche in hemophilia A, but is way behind

Sionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for its own listing

Pfizer hires Novartis oncology exec to steer its cancer ambitions

A GSK-led con­sor­tium looks to break ground with a new class of an­tibi­ot­ic, push­ing in­to a piv­otal

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

A GSK-led consortium looks to break ground with a new class of antibiotic, pushing into a pivotal